Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10331452 | 0.93 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL3402444 | 0.91 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| Acetic Acid SCHEMBL28083299 | 0.88 | KMT2A (0.60) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6523383 | 0.87 | KMT2A (0.62) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL25028453 | 0.86 | KMT2A (0.60) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18897531 | 0.85 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL6523393 | 0.85 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10331456 | 0.85 | EPHX2 (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6526112 | 0.81 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6524612 | 0.80 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028674-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-RE46605-E1 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-RE46608-E1 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-3210972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | Catabasis Pharmaceuticals, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20160346397-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9486534-B2 | Niacin conjugated fatty acid mixtures and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2473045-B1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9278136-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9238077-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140113940-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| WO-2013177536-A2 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-8304552-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304551-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120264791-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120252850-A1 | NIACIN CONJUGATED FATTY ACID MIXTURES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120184585-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2473045-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011028689-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110053990-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053990-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | RAB9A 1912/4885NPC1 29/4885SMN1; SMN2 1436/4885 |
| US-20120184585-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | RAB9A 1912/4885NPC1 29/4885SMN1; SMN2 1436/4885 |
| US-20140113940-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | RAB9A 1912/4885NPC1 29/4885SMN1; SMN2 1436/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | RAB9A 1266/4885NPC1 71/4885SMN1; SMN2 4499/4885 |
| US-20120264791-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | RAB9A 1912/4885NPC1 29/4885SMN1; SMN2 1436/4885 |
| US-20120252850-A1 | NIACIN CONJUGATED FATTY ACID MIXTURES AND THEIR USES | FABP1, NAMPT, ADH1B | RAB9A 2278/4885NPC1 40/4885SMN1; SMN2 1674/4885 |
| US-20180028674-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | RAB9A 1912/4885NPC1 29/4885SMN1; SMN2 1436/4885 |
| US-20160346397-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | RAB9A 1912/4885NPC1 29/4885SMN1; SMN2 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.